Menu
Search
|

Menu

Close
X

ITUS Corp ITUS.OQ (NASDAQ Stock Exchange Capital Market)

3.16 USD
-0.26 (-7.60%)
As of Feb 16
chart
Previous Close 3.42
Open 3.38
Volume 46,485
3m Avg Volume 155,651
Today’s High 3.47
Today’s Low 3.08
52 Week High 6.42
52 Week Low 0.60
Shares Outstanding (mil) 15.32
Market Capitalization (mil) 42.44
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
9
EPS (USD)
FY17
-0.631
FY16
-0.574
FY15
-0.181
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
24.61
Price to Sales (TTM)
vs sector
75.44
53.68
Price to Book (MRQ)
vs sector
7.63
2.68
Price to Cash Flow (TTM)
vs sector
--
16.85
Total Debt to Equity (MRQ)
vs sector
36.44
96.79
LT Debt to Equity (MRQ)
vs sector
0.00
74.65
Return on Investment (TTM)
vs sector
-75.74
7.22
Return on Equity (TTM)
vs sector
-174.62
12.42

EXECUTIVE LEADERSHIP

Amit Kumar
Chairman of the Board, President, Chief Executive Officer, Since 2017
Salary: $300,000.00
Bonus: $200,000.00
Michael Catelani
Chief Financial Officer, Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Arnold Baskies
Director, Since 2016
Salary: --
Bonus: --
Dale Fox
Independent Director, Since 2014
Salary: --
Bonus: --
John Monanhan
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Industrials
Industry: Business Support Services
Address:

3150 Almaden Expy Ste 250
SAN JOSE   CA   95118-1250

Phone: +1310.4845200

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Instead of seeking to alter or boost the body's immune system and its ability to destroy cancer cells, the Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients, and in distinguishing the blood of healthy patients from the blood of cancer patients.

SPONSORED STORIES